

Avidan U Neumann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3424731/publications.pdf>

Version: 2024-02-01

36
papers

2,861
citations

257357

24
h-index

345118

36
g-index

37
all docs

37
docs citations

37
times ranked

4126
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential effects of lung inflammation on insulin resistance in humans and mice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2482-2497.	2.7	3
2	Considering Personalized Interferon Beta Therapy for COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	9
3	Distinct cytokine profiles associated with COVID-19 severity and mortality. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 2098-2107.	1.5	47
4	Tocilizumab in COVID-19 therapy: who benefits, and how?. <i>Lancet, The</i> , 2021, 398, 299-300.	6.3	6
5	The power and potential of BIOMAP to elucidate host-microbiome interplay in skin inflammatory diseases. <i>Experimental Dermatology</i> , 2021, 30, 1517-1531.	1.4	5
6	Pollen exposure weakens innate defense against respiratory viruses. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 576-587.	2.7	84
7	The skin microbiome as a clinical biomarker in atopic eczema: Promises, navigation, and pitfalls. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 93-96.	1.5	29
8	Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2829-2845.	2.7	403
9	Skin pH-dependent <i>Staphylococcus aureus</i> abundance as predictor for increasing atopic dermatitis severity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2888-2898.	2.7	41
10	Physical and immunological barrier of human primary nasal epithelial cells from non-allergic and allergic donors. <i>World Allergy Organization Journal</i> , 2020, 13, 100109.	1.6	25
11	Defining biomarkers to predict symptoms in subjects with and without allergy under natural pollen exposure. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 583-594.e6.	1.5	21
12	The Role of Pre-existing Cross-Reactive Central Memory CD4 T-Cells in Vaccination With Previously Unseen Influenza Strains. <i>Frontiers in Immunology</i> , 2019, 10, 593.	2.2	27
13	Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 142-154.	1.5	135
14	Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 872-881.e6.	0.6	265
15	Relations between epidermal barrier dysregulation and <i>Staphylococcus</i> species-dominated microbiome dysbiosis in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1643-1647.e12.	1.5	56
16	Type 3 innate lymphoid cells induce proliferation of CD94+ natural killer cells. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1156-1159.e7.	1.5	1
17	Pro-Inflammatory versus Immunomodulatory Effects of Silver Nanoparticles in the Lung: The Critical Role of Dose, Size and Surface Modification. <i>Nanomaterials</i> , 2017, 7, 300.	1.9	48
18	Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection. <i>PLoS Pathogens</i> , 2017, 13, e1006299.	2.1	12

#	ARTICLE	IF	CITATIONS
19	IMSEQ—a fast and error aware approach to immunogenetic sequence analysis. <i>Bioinformatics</i> , 2015, 31, 2963-2971.	1.8	98
20	Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. <i>Digestive and Liver Disease</i> , 2015, 47, 233-241.	0.4	4
21	Comment on “Tracking donor-reactive T cells: Evidence for clonal deletion in tolerant kidney transplant patients” <i>Science Translational Medicine</i> , 2015, 7, 297le1.	5.8	4
22	Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. <i>Antiviral Research</i> , 2011, 90, 183-186.	1.9	65
23	Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells. <i>Hepatology</i> , 2010, 52, 875-885.	3.6	63
24	Early prediction of sustained virological response at day 3 of treatment with albinterferon- α 2b in patients with genotype 2/3 chronic hepatitis C. <i>Liver International</i> , 2009, 29, 1350-1355.	1.9	13
25	Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C. <i>Journal of Hepatology</i> , 2009, 51, 21-28.	1.8	25
26	Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. <i>Antiviral Therapy</i> , 2009, 14, 591-595.	0.6	35
27	Hepatitis B viral kinetics: A dynamic puzzle still to be resolved. <i>Hepatology</i> , 2005, 42, 249-254.	3.6	36
28	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005, 43, 250-257.	1.8	143
29	Mathematical modeling of primary hepatitis C infection: Noncytolytic clearance and early blockage of virion production. <i>Gastroenterology</i> , 2005, 128, 1056-1066.	0.6	109
30	First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. <i>Journal of Viral Hepatitis</i> , 2002, 9, 340-345.	1.0	74
31	Hepatitis C Virus Kinetics. <i>Antiviral Therapy</i> , 2000, 5, 85-90.	0.6	87
32	A Polymorphism in the Regulatory Region of the CC-Chemokine Receptor 5 Gene Influences Perinatal Transmission of Human Immunodeficiency Virus Type 1 to African-American Infants. <i>Journal of Virology</i> , 1999, 73, 10264-10271.	1.5	123
33	A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. <i>Nature Medicine</i> , 1998, 4, 350-353.	15.2	415
34	Chemokine Coreceptor Usage by Diverse Primary Isolates of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 1998, 72, 9307-9312.	1.5	122
35	Rapid, Transient Changes at the <i>env</i> Locus of Plasma Human Immunodeficiency Virus Type 1 Populations during the Emergence of Protease Inhibitor Resistance. <i>Journal of Virology</i> , 1998, 72, 2416-2421.	1.5	39
36	Interferon Resistance of Hepatitis C Virus Genotype 1b: Relationship to Nonstructural 5A Gene Quasispecies Mutations. <i>Journal of Virology</i> , 1998, 72, 2795-2805.	1.5	189